Oral medication options, incorporated in 2018 and 2019, also registered an increasing trend in the number of patients in use (dimethyl fumarate 120 mg = 118%; dimethyl fumarate 240 mg = 222%; and teriflunomide = 78%; between 2019 and 2020), which did not happen with the others.
← all excerpts
External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis.
1
—
—